Cervical Cancer — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Proceed with pembrolizumab and platinum-paclitaxel because bevacizumab is optional in the appraised regimen
TA939 recommends pembrolizumab plus platinum-based chemotherapy and paclitaxel with or without bevacizumab for CPS at least 1 disease. A fistula makes bevacizumab unattractive, but does not remove the pembrolizumab-chemotherapy option because bevacizumab is explicitly optional. Pembrolizumab monotherapy, cetuximab substitution and default topotecan are not the appraised first-line regimen.
Reference: NICE TA939 pembrolizumab plus chemotherapy with or without bevacizumab for cervical cancer (Published December 2023): https://www.nice.org.uk/guidance/ta939/chapter/1-Recommendations